Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

Share Price is delayed by 15 minutes
Get Live Data
66.20    -1.80 (-2.65%)
Bid:
65.90
Ask:
66.70
Spread: 0.80 (1.214%)
Market Cap: £584.83m
IPO Live PriceLast checked at - London Stock Exchange

Intraday Ip Group Share Chart

Director/PDMR Shareholding

23 Apr 2026 12:18

RNS Number : 7025B
IP Group PLC
23 April 2026
 

 

FOR RELEASE ON

23 April 2026

 

IP Group plc - Employee Share Schemes; Director/PDMR shareholding

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), which invests in breakthrough science and innovation companies with the potential to create a better future for all, announces the following in connection with its employee share schemes.

 

Release of Deferred Bonus Awards

 

On 22 April 2026, the Group's executive directors and one other person discharging managerial responsibilities ("PDMR") received a total of 168,957 ordinary shares of two pence each ("Shares"), resulting from the release of Deferred Bonus Awards granted in relation to the partial deferral of annual bonuses for the 2023 and 2024 financial years. 

 

The delivery of the awards was satisfied through the transfer of Shares from the Company's employee benefit trust (the "EBT"), with the balance being settled by cash payments in an amount sufficient to meet the relevant individuals' income and other tax liabilities in accordance with the rules of the IP Group Share Plan ("Share Plan"). 

The Shares transferred to the Group's executive directors will be held by the EBT on behalf of, and as nominee for, the executive directors in order to facilitate the application of the Group's Post Cessation Shareholding Policy.

 

A copy of the Share Plan can be found at:

https://www.ipgroupplc.com/investors/corporate-governance

 

 

Shares in issue

As at 22 April, the Company had 883,427,642 Shares in issue and no Shares held in treasury.

The following information is being disclosed pursuant to the requirements of MAR.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

 

DBA Release

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Greg SmithDavid BaynesMark Reilly

2

Reason for the notification

a)

Position/status

Director Chief Executive OfficerDirector Chief Operating and Financial OfficerPDMR Managing Partner

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

IP Group plc

b)

Legal Entity Identifier

213800HG22UM138WFG43

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 2p each in IP Group plc

 ISIN: GB00B128J450

b)

Nature of the transaction

Release of the 2024 Deferred Bonus Awards and 2025 Deferred Bonus Awards

c)

Currency

GBP

d)

Price(s) and volume(s)

Name(s)

Price(s)

Volume(s)

Greg Smith

Conditional Share Award

67,116

David Baynes

Conditional Share Award

41,435

Mark Reilly

Conditional Share Award

60,406

e)

Aggregated information

-Aggregated volume

- Price

- Aggregated total

 

168,957

 

63.7p

£107,625.61

f)

Date of the transaction

22 April 2026

g)

Place of the transaction

London Stock Exchange, Main Market

 

 

 

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Liz Vaughan-Adams, Communications

 

Portland

 

 

Alex Donaldson

+44 (0) 20 7444 0062/+44 (0) 7979 853802

 

 

 

+44 (0) 7516 729702

 

 

Notes for editors

 

About IP Group

 

IP Group accelerates the impact of science for a better future. As the most active UK based, early stage science and technology investor, we develop and support some of the world's most exciting businesses in healthtech, deeptech and cleantech. Including through Parkwalk, the UK's largest growth EIS fund manager, we back world-changing innovation emerging in leading universities and research institutions. Our specialist investment team combines sector expertise with an international approach. Together we have a strong track record of success, having backed high-profile companies including Oxford Nanopore Technologies plc, Hinge Health, Featurespace, First Light Fusion, Hysata, and Oxa. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

 

For more information, please visit our website at www.ipgroupplc.com.

 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHPPUAGCUPQGGW
Date   Source Headline
3rd Jun 20267:00 amRNSHolding(s) in Company
2nd Jun 20267:00 amRNSHolding(s) in Company
29th May 20267:00 amRNSHolding(s) in Company
29th May 20267:00 amRNSHolding(s) in Company
28th May 20267:00 amRNSHolding(s) in Company
13th May 20265:30 pmRNSNotice of AGM
12th May 20269:10 amRNS-REnterprise reports positive results from P2 trial
11th May 20264:25 pmRNSHolding(s) in Company
11th May 20264:19 pmRNSHolding(s) in Company
7th May 20267:00 amRNSAppointment of Chair Designate
23rd Apr 202612:18 pmRNSDirector/PDMR Shareholding
21st Apr 20267:00 amRNS-RFirst Light announces £25m successful first close
15th Apr 20265:00 pmRNSAnnual Financial Report
14th Apr 20269:25 amRNSHolding(s) in Company
30th Mar 20262:00 pmRNSNew climate fund launch with Australia's CEFC
26th Mar 202610:00 amRNSHolding(s) in Company
25th Mar 20262:00 pmRNSHolding(s) in Company
19th Mar 20265:30 pmRNSHolding(s) in Company
17th Mar 20267:00 amRNSIP Group plc 2025 Annual Results Release
17th Mar 20267:00 amRNSIP Group plc 2025 Annual Results Release
13th Mar 20265:45 pmRNSHolding(s) in Company
12th Mar 202611:00 amRNSHolding(s) in Company
12th Mar 20269:00 amRNSNotice of Results
12th Mar 20269:00 amRNSNotice of Results
4th Mar 20267:00 amRNS-RPortfolio company Oxa raises $103m in Series D
26th Feb 20262:53 pmRNSHolding(s) in Company
26th Feb 20269:30 amRNSHolding(s) in Company
25th Feb 20265:51 pmRNSHolding(s) in Company
11th Feb 20269:01 amRNS-RMicrobiotica announces positive P1b trial results
30th Jan 20267:00 amRNSHolding(s) in Company
29th Jan 20267:00 amRNSHolding(s) in Company
20th Jan 202612:36 pmRNSHolding(s) in Company
14th Jan 20267:00 amRNSDirectorate change
14th Jan 20267:00 amRNSHolding(s) in Company
12th Jan 20266:25 pmRNSHolding(s) in Company
7th Jan 20262:06 pmRNSPulmocide announces termination of Phase 3 study
2nd Jan 20267:00 amRNSHolding(s) in Company
2nd Jan 20267:00 amRNSHolding(s) in Company
18th Dec 20254:13 pmRNSHolding(s) in Company
18th Dec 20254:13 pmRNSHolding(s) in Company
8th Dec 20257:00 amRNSHolding(s) in Company
5th Dec 20255:26 pmRNSHolding(s) in Company
4th Dec 20254:13 pmRNSHolding(s) in Company
1st Dec 20255:37 pmRNSTotal Voting Rights
20th Nov 20257:00 amRNSCompletion of share buyback programme
19th Nov 20257:00 amRNSTransaction in Own Shares
18th Nov 20257:00 amRNSTransaction in Own Shares
17th Nov 20251:10 pmRNSArtios completes oversubscribed $115m financing
14th Nov 20255:47 pmRNSTransaction in Own Shares
14th Nov 20258:20 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.